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Abstract
Background: Human cervical cancer oncoprotein 1 (HCCR-1), reported as a negative regulator of p53, is over-
expressed in a variety of human cancers. However, it is yet unknown whether HCCR-1 plays any role in pancreatic 
cancer development. The aim of this study was to investigate the effect of epidermal growth factor on the expression 
of HCCR in pancreatic cancer cells, and to explore if PI3K/Akt/mTOR signaling pathway mediated this expression.
Methods: A polyclonal antibody against HCCR protein was raised by immunizing Balb/c mice with the purified 
recombinant protein pMBPc-HCCR. Tissue samples were constructed on a tissue chip, and the expression of HCCR was 
investigated by immunohistochemistry assay and Western blotting. Pancreatic cell line, PANC-1 cells were stably 
transfected with plasmids containing sense-HCCR-1 fragment and HCCR siRNA fragment. MTT and transwell assay 
were used to investigate the proliferation and invasion of stable tansfectants. The specific inhibitor of PI3K and mTOR 
was used to see if PI3K/mTOR signal transduction was involved in the induction of HCCR gene expression. A Luciferase 
assay was used to see if Akt can enhance the HCCR promoter activity.
Results: HCCR was up-regulated in pancreatic tumor tissues (mean Allred score 4.51 ± 1.549 vs. 2.87 ± 2.193, P < 0.01), 
especially with high expression in poorly differentiated pancreatic cancer. The growth of cells decreased in HCCR-1 
siRNA transfected cells compared with vector transfectants. The number of invasion cells was significantly lower in 
HCCR-1 siRNA transfected cells (24.4 ± 9.9) than that in vector transfectants (49.1 ± 15.4). Treatment of PANC-1 cells 
with epidermal growth factor increased HCCR protein level in a dose- and time-dependent manner. However, 
application of LY294002 and rapamycin caused a dramatic reduction of epidermal growth factor-induced HCCR 
expression. Over-expression of exogenous constitutively active Akt increased the HCCR promoter activity; in contrast, 
dominant negative Akt decreased the promoter activity.
Conclusions: EGF-induced HCCR-1 over-expression is mediated by PI3K/AKT/mTOR signaling which plays a pivotal 
role in pancreatic tumor progression, suggesting that HCCR-1 could be a potential target for cancer therapeutics.
Background
Pancreatic cancer is one of most common malignant
tumors with poor prognosis, and its incidence is on the
rise globally. The five-year survival rate is less than 5 per-
c e n t  a m o n g  pa n cr ea t i c  ca n c e r  pa t i e n ts  wi t h  r a r e  c o m -
plete remission [1-5]. Although a large number of
potential proteins and gene-based markers have been
used for diagnosis of pancreatic cancer, the established
marker so far is CA19-9 with better diagnostic sensitivity
and specificity of 68% and 76%, respectively [6-8].
Recent molecular investigations have elucidated com-
plex genetic mechanisms of cancer that especially involve
multiple signal transduction pathways. These findings
enable us to develop molecular medicines targeting spe-
cific genetic molecules in the pathways. Cancer is a
genetic disease; i.e., dysfunctions of multiple genes
including active oncogenes and inactive tumor suppres-
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sor genes play crucial roles in the development and pro-
gression of the disease. Many of these dysfunctioning
molecules comprise signaling pathways, which indicates
that cancer is a signaling disorder. Aberrantly activated
signal transduction systems are vital for the sustenance of
cancer, which is often compared to a state of "addiction".
This extent of dependence upon aberrant signaling sys-
tems in cancer implies that shutting down the signaling
would cause the cancer to vanish.
The PI3K-Akt pathway is major signaling pathway
involved in the oncogenesis of many types of cancers [9].
PI3K is a heterodimer of the 85-kDa and 110-kDa sub-
units and has a tyrosine kinase activity. PI3K mediates an
activating signal from the growth factor receptors to Akt,
which is a kinase that translocates into the nucleus and
phosphorylates a variety of target molecules to mediate
signals, including mTOR. mTOR is a serine/threonine
kinase implicated in the regulation of translation initia-
tion [10]. The function of m TOR is associated with the
PI3K-Akt pathway via TSC [11]. Although no mutations
in PI3K or Akt1 have been reported so far, evidence sug-
gests that the PI3K/Akt pathway is active in pancreatic
cancers [12-14], which indicates that the pathway is a
putative therapeutic target in such cancers.
Human cervical cancer oncogene (HCCR) was firstly
identified in primary cervical cancers and cervical cancer
cell lines by using differential display RT-PCR approach
[15-17]. The HCCR gene is classified into two isoforms,
wild type HCCR-1 which encodes 360 amino acids (42
KD) and its alternative splicing variant, HCCR-2 which
encodes 304 amino acids (36 KD) [15]. Previous study
suggested that nude mice injected with NIH/3T3 cells
stably transfected with HCCR formed tumors within 4
weeks. NIH/3T3 cells stably transfected with HCCR frag-
ment showed increased transformation efficiency and
more colony formation in soft agar, and it is also found
that HCCR involves in p53 stabilization, decreased
expressions of p53-responsive gene such as p21 and Bax,
suggesting that HCCR may function as a negative regula-
tor of p53 [15,16]. HCCR was also validated as a bio-
marker for both human hepatocellular carcinoma and
breast cancer [18,19]. HCCR-1 and DP1 which play a
tumor-suppressor role in colorectal cancer were sup-
posed to regulate each other negatively by interaction
[20].
To determine the regulatory pathway involved in the
HCCR-1 gene expression, Cho GW et al searched the 5-
flanking region of HCCR-1 and found that the HCCR-1
oncogene expression is regulated by the PI3K/Akt signal-
ing pathway in K562, MCF-7 and A549 cells [21]. HCCR-
1 is not only over-expressed in cervical cancer tissues, but
also in several other cancers including leukemia, lym-
phoma, and carcinomas of breast, kidney, ovary, stomach,
and colon [15]. Despite of this, little is known about the
role of HCCR-1 in pancreatic cancer development. Here
in this study, we demonstrate that HCCR-1 is responsible
for pancreatic cancer via EGF mediated-PI3K/Akt/mTOR
signaling pathway.
Methods
Preparation of HCCR polyclonal antibody
The cDNA encoding the C-terminus of HCCR (from the
167th to 360th amino acid residues) was cloned into the
pMBP-c containing tags of MBP and polyHis (Fermentas
MBI) vector. The construct was then transformed into
the E. coli Top10F' (Fermentas MBI). Expression of
HCCR C-terminal polypeptide was induced by IPTG (0.4
mM/L). The recombinant product was purified by nick-
nitrilotriacetic acid (Ni-NTA)-affinity chromatography.
BALB/c mice were immunized by intrasplenic deposition
of 1 μg of the purified fusion protein attached to PVDF
membrane for the first time [22]. Two weeks later, mice
were immunized again by intra-peritoneal injection with
50 μg of polypeptide mixed with Freund's complete adju-
vant. The polyclonal anti-HCCR serum was tested for its
efficiency and specificity by indirect ELISA and Western
blot.
Sample selection and tissue chip construction
178 cases of pancreatic tumor, 47 cases of paraneoplastic
tissue and benign tumor were obtained from sample
library of Shanghai Biochip Corporation, including 159
cases of adenocarcinoma, 7 cases of adenosquamous car-
cinoma, 8 cases of mucoid adenocarcinoma, 2 cases of
carcinoid, 1 case of spindle cell malignant tumor and 1
case of acinic cell carcinoma, 36 cases of paraneoplastic
tissues and 11 cases of pancreatic benign tumors. The age
of the patients ranged from 30 years to 86 years. Of the
patients with pancreatic carcinoma, 111 were males, and
6 7  p a t i e n t s  w e r e  f e m a l e s .  P a t h o l o g i c  d i a g n o s i s  w a s
proved by two experienced pathologists from two differ-
ent hospitals. 99 cases accompany nerve infiltration and
36 cases with lymph node metastasis were determined.
Tissue chip was constructed by Shanghai Biochip Corpo-
ration.
Cell Culture and Chemical Compounds
Human cell lines from ATCC, were maintained in Dul-
becco's minimal essential medium(Gibco, Grand Island,
NY) supplemented with 10% fetal bovine serum, 100
units/mL penicillin, and 100 μg/mL streptomycin at 37°C
in a 5% CO2-humidified atmosphere. Cells were plated at
5 × 105 per well in 6-well plates. For growth factor depri-
vation, the medium was made without serum, EGF, and
insulin. Cells were grown to 60% to 70% confluency, then
starved in serum-free DMEM for 24 hours, then the cellsXu et al. BMC Cancer 2010, 10:161
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were pretreated with inhibitors for 1 hours incubated in
the presence of EGF for 24 hours and extracted and sub-
jected to Western blot analysis. The human recombina-
tion protein EGF was purchased from Peprotech.
LY294002 were purchased from Cell Signaling Technol-
ogy. Rapamycin were obtained from Sigma.
DNA constructs and transfection
The constructs of Akt kinase, constitutively active Akt
kinase, and dominant-negative Akt kinase (K179M) in
the pCMV-6 vector or in the retrovirus vector pLNCX
were generously provided by Thomas Franke [23,24]. The
constitutively active Akt kinase and dominant-negative
Akt kinase were re-cloned into pcDNA3.1 vector in our
laboratory. The construct of HCCR-1 in pcDNA3.1 was
kindly gifted from Dr. Jin Woo Kim [21] (The Catholic
University of Korea). HCCR-1 siRNA were constructed in
pGCsi-H1/Hygro/NEGative vector by GeneChem com-
pany, Shanghai, China. The sequences of the selected
region to be targeted by siRNA for HCCR were: SR54-3F:
TGCTGAATCACATCGGAATGCTCATTGTTTTGGC
CACTGACTGACAATGAGCACCGATGTGATT; and
SR54-3R:
CCTGAATCACATCGGTGCTCATTGTCAGTCAGTG
GCCAAAACAATGAGCATTCCGATGTGATTC.
PANC-1 cells in exponential growth were seeded into 6-
well plates at a concentration of 1 × 105/ml. After 24
hours, cells were transfected with 2 μg of DNAs of consti-
tutively active Akt (CA-Akt), dominant negative Akt(DN-
Akt), HCCR-1 siRNA and HCCR-1-pcDNA3.1 by lipo-
fectmine 2000 (Invitrogen, Carlsbad, CA), respectively.
Culture medium was replaced after 6 hours of incubation,
and medium containing 500 μg/mL G418 was used for
screening 48 hours later. About 3 weeks later, ten G418-
resistant clones were selected with a cloning ring for
amplification in culture.
Immunohistochemistry
The immunostaining was performed manually at room
temperature by using the UltraSensitive SP immunohis-
tochemistry kit (Maixin Biotech, Fuzhou). PBS replaced
the murine polyclonal anti-HCCR serum (1:100) as a neg-
ative control. Using the Allred 8-unit system, we deter-
mined the tumor epithelial cells proportion score and
intensity score. The stain was examined by 2 independent
pathologists using the Allred 8-unit system with the com-
bination of a proportion score from 0 to 5 and an inten-
sity score from 0 to 3. The proportion score included the
fraction of positively stained tumor cells and was as fol-
lows: 0 = none, 1 = <1/100th; 2 = 1/100th to 1/10th; 3 = 1/
10th to 1/3; 4 = 1/3 to 2/3; 5 = >2/3. The staining intensity
score was as follows: 0 = none; 1 = weak; 2 = intermedi-
ate; 3 = strong [25,26].
Western Blot Analysis
For Western blot analysis, tissues and cells were lysed by
lysis buffer, and the lysates were collected. The protein
were diluted in the sample buffer(250 mM Tris-HCl, 4%
SDS, 10% glycerol, 0.006% bromophenol blue and 2% β-
mercaptoethanol) and boiled for 5 min after measured
the concentration with the BCA protein assay. Equivalent
volumes of lysates containing 20 ug of total protein were
loaded and size-fractionated using 10% SDS-polyacryl-
amide gels. Proteins were transferred onto nitrocellulose
membrans at 100 V for 90 min. Subsequently, membranes
were incubated with 1:500 dilution of murine polyclonal
anti-HCCR-1 antibody (Tubulin-α as positive control) in
blocking solution overnight at 4. Next, the membranes
were washed and incubated with a horseradish peroxide-
conjugated goat anti-mouse secondary antibody diluted
i n  b l oc ki n g  b u ff e r .  P r o t e i n s  w e r e  d e t ect ed  b y  u s i n g  a n
enhanced chemiluminescence Western blotting detection
kit (Pierce Biotech).
MTT assay
PANC-1 cells stably transfected with HCCR-1, HCCR-1
siRNA and vector plasmid were plated into 96-well plates
in 1 × 103 cells/100 μl DMEM (Gibco)/well. 20 μl of MTT
solution (Sigma) was added into each well daily from the
2nd to 5th day, and plates were incubated for 4 h at 37°C.
After removal of the supernatant, 200 ml of dimethyl sul-
foxide (DMSO; Sigma) was added to dissolve the crystals.
Absorbance values (A) were measured at a wavelength of
490 nm with a microplate reader. Growth curve was
made according to the values of 490 nm wavelength light
absorption in the three groups The mean ± SD of tripli-
cate assays for each cell line is shown.
Invasion assay
Matrigel invasion assay was performed by using a 24-well
transwell plates(costar) with polycarbonate filters (pore
size, 8 μm). The upper side of polycarbonate filter was
coated with matrigel (50 μg/ml, BD Biosciences). The
chambers were incubated at 37°C with 5% CO2 for 2 h to
allow the matrix to form a continuous thin layer. Then the
cells stably transfected with HCCR siRNA plasmid and
vector plasmid were harvested and 4 × 105 cells in 200 μl
of 0.1% bovine serum albumin were placed in the upper
chamber. The lower chamber was filled with 10% serum-
medium (700 μl). Cells were cultured for 24 h at 37°C in
5% CO2. Cells on the upper surface of the filter were
removed using a cotton swab. Cells invading through the
Matrigel and filter to the lower surface were fixed with 4%
neutral-buffered formalin and stained with Giemsa. The
cell numbers in five fields (up, down, median, left, right.
×200) were counted for each chamber, and the average
value was calculated. Assays were done in triplicate for
each experiment.Xu et al. BMC Cancer 2010, 10:161
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Luciferase assay
PANC-1 cells stably transfected with vector, constitu-
tively active Akt, or dominant-negative Akt were plated at
1 × 105 c e l l s  i n  s ix - w e l l  p l a t e s  a n d  g r o w n  f o r  2 4  h o u r
before transfection with lipofectime. The cells were co-
transfected with three pGL3-Basic vector containing the
HCCR-1 proximal promoter regions [pGL3-P1196(+30 to
-1166), pGL3-P504 (+30 to -474), pGL3-P423(-52 to -
474)] and internal control pRL-CMV using Lipo-
fectamine 2000. The luciferase activity was measured
after 24 h of transfection with the luciferase assay kit as
indicated by the manufacturer. PRL-CMV was used as an
internal standard to normalize the luciferase activity.
Statistical analysis
All the data were analyzed by SPSS13.0. The positive
expression of HCCR in each group was compared using
test and ANOVA. The MTT results the data of luciferase
assay was analyzed using ANOVA. A test was run for all
sites combined and one for each of the site groupings.
Results
Antibody preparation of HCCR
The polyclonal antibody against HCCR protein, prepared
by immunizing Bclb/c mice with the purified recombi-
nant protein pMBPc-HCCR-His, had both high efficiency
and specificity which were tested by indirect ELISA
(Antibody titer: 1:10000) and Western blot. Western blot-
ting using this polyclonal antiserum showed strong single
bands corresponding to HCCR (Mr 36,000) in HCC tis-
sues, which did not react to the monoclonal antibody
against MBP and His. Fusion protein pMBPc-HCCR-His
served as a positive control (Fig. 1A). The bands corre-
sponding to HCCR (Mr 36,000) disappeared when the
antiserum was pre-absorbed with another recombinant
protein HCCR-GST (Fig. 1B), suggesting that the poly-
clonal antibody against HCCR protein had high specific-
ity.
HCCR-1 overexpression may enhance the pancreatic tumor 
progression
It has been shown that HCCR-1 is overexpressed in sev-
eral human cancers [15]. To investigate whether HCCR-1
plays any role in pancreatic cancer development, we
firstly examined the pancreatic cancer cell growth in vitro
after transfecting PANC-1 cells with HCCR-1 expressing
DNA constructs. PANC-1 cells carrying empty vector
(pcDNA3.1) were used as controls (Fig. 2A). Our result
reveals that HCCR-1 enhances the growth of PANC-1
cells in vitro by 1.5 fold over 3-day incubation period (Fig.
2B). We also obtained the PANC-1 cells which were sta-
bly transfected with plasmid containing HCCR siRNA
fragment and vector (Fig. 2C). As expected, the prolifera-
tion was inhibited in PNAC1 cells stably transfected with
HCCR siRNA (Fig. 2D). The growth decreased by 0.65
times and 0.68 times in HCCR-1 siRNA transfected cells.
The number of invasion cells was significantly lower in
PNAC1 cells transfected with HCCR-1 siRNA (24.4 ± 9.9)
than that in vector transfectants (49.1 ± 15.4) (Fig. 2E).
To determine the cellular localization of HCCR-1 pro-
tein and its distribution among different tissues, we made
the tissue chips implanted with these pathologically dif-
ferent tissues (described in Materials and Method sec-
tion). HCCR-1 expression was observed in most of
pancreatic tumor tissues with the mean Allred score was
4.51 ± 1.549 (Fig. 2F). In contrast, HCCR-1 was expressed
at low levels in paraneoplastic tissues and benign tumors
and its mean score was 2.87 ± 2.193 (p < 0.001) (Table 1).
This result was further supported by the western blot
analysis on the same tissues used in the immunohis-
tochemical analyses. As shown in Fig. 2G, strong expres-
sion of HCCR-1 was detected in the pancreatic
carcinomas compared with which in paraneoplastic tis-
sues. Moreover, it was interesting to note that HCCR-1
Figure 1 Analysis of the high specificity of the polyclonal anti-
body against HCCR protein by Western blotting. A) Lane 1, recom-
binant pMBP-c-HCCR-His protein (positive control); Lane 2-7, cell lysate 
from hepatocellular carcinoma tissues. Lane 2-7 showed strong bands 
by using the polyclonal antibody against HCCR(Mr 36,000) while they 
showed no bands by using the monoclonal antibody against MBP and 
His. B) Lane 1-5, tissues of hepatocellular carcinoma. Lane 1 showed 
strong band corresponding to HCCR by using the polyclonal antibody 
against HCCR. The band was weaken gradually and then disappeared 
when the antiserum was preabsorbed with gradually increased con-
centration of recombinant pGEM-HCCR (with a GST tag) protein from 
Lane 2 to Lane 5.Xu et al. BMC Cancer 2010, 10:161
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Figure 2 Overexpression of HCCR-1 induces the proliferation of PANC-1 cells. A) PANC-1 cells were transfected with control empty vector and 
HCCR-1 gene. B) HCCR-1 accelerated the proliferation of PANC-1 cells by 1.5 fold compared to control. The measurement of proliferation rate was 
performed by MTT assay. Values represent the mean ± SEM, Groups with annotations of H1 and H2 are significantly different with Vector, P < 0.01, 
two-way ANOVA. C) PANC-1 cells were transfected with HCCR-1 siRNA and control empty vector. D) Knock-down of HCCR-1 decreased the prolifera-
tion of PANC-1 cells MTT assay. Values represent the mean ± SEM, Groups with annotations of siRNA were significantly different with Vector, P < 0.01, 
two-way ANOVA. E) The invasiveness of HCCR-1 siRNA and vector transfectants were assessed by incubating cells in transwell plates(Costar) with poly-
carbonate filters for 24 h using 10% FBS as a chemoattractant. Cells invaded through the matrigel and filtered to the lower surface were fixed with 4% 
neutral-buffered formalin and stained with Giemsa. The number of invasion cells was significantly lower in HCCR-1 siRNA transfectants (24.4 ± 9.9) 
than in vector control(49.1 ± 15.4), *P < 0.01. Each experiment was repeated for three times. F) Immunohistochemical staining of pancreatic cancer 
tissues on a tissue chip. Strong straining of HCCR-1 in a pancreatic carcinoma(the upper two pictures). Expression of HCCR-1 in a paraneoplastic tis-
sue(the two pictures below). The staining was graded according to Allred score system. G) The expression of HCCR-1 was analyzed by performing 
western blotting in the same tissues used in immunohistochemical staining. Lanes 1 to 3, paraneoplastic tissues; lanes4 to 7, pancreatic tumor tissues. 
Tubulin was used as a loading control.
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expression is associated with histological grade (p =
0.006), the mean score of histological stage II, III (4.53 ±
1.398 and 4.63 ± 1.847) were higher than of histological
stage I (3.37 ± 1.461, P < 0.01 respectively), there is no sig-
nificant difference between stage II and stage III (P =
0.738). Whereas it was not related to clinicopathological
factors such as age, sex, nerve infiltration and lymph node
metastasis (Table 2). This tissue expression profile sug-
gests that HCCR-1 may function in the pancreatic tumor
progression, possibly involving the cellular tumorigenesis
signaling pathway.
HCCR-1 expression is linked to EGF/PI3K/Akt/mTOR 
signaling in PANC-1 cells
EGF stimulation on PANC-1 cells was commenced to
determine whether and how EGF regulates the expres-
sion of the HCCR-1 crucial for the pancreatic cancer
growth and survival. PANC-1 cells express more HCCR-1
in a dose- and time-dependent manner (Figs. 3A and 3B)
when they are stimulated with EGF. The HCCR-1 expres-
sion was gradually elevated from 8 h up to 72 h incuba-
tion time point, suggesting that EGF signaling is involved
in the induction of HCCR-1 expression. The same results
Table 2: Relations between HCCR-1 expression and clinicopathological characteristics of tumors
Clinical 
characteristics
cases mean score t P
Age
≤60 80 4.64 1.027 0.306
>60 98 4.40
Sex
Male 111 4.52 0.187 0.852
Female 67 4.48
Nerve infiltration
Yes 99 4.45 0.805 0.42
No 70 4.64
Lymph node metastasis
Yes 36 4.69 0.731 0.466
No 134 4.49
Histological grades F
I 19 3.37 5.316 0.006*
II 115 4.53
III 30 4.63
*P < 0.01
Table 1: HCCR-1 expression in pancreatic cancer tissues, paraneoplastic tissues/benign tumor tissues
cases mean score t P
Pancreatic cancer 178 4.51 5.853 0.000*
Paraneoplastic tissues/
benign tumors
47 2.87
*P < 0.01Xu et al. BMC Cancer 2010, 10:161
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Figure 3 HCCR-1 overexpression is mediated with EGF-induced PI3K/AKT/mTOR signaling. Western blot analysis of HCCR-1 expression in 
PANC-1 cells stimulated with EGF. A) Dose dependency (at 24 h). Total protein were extracted from serum starved PANC-1 cells treated with EGF at 
different concentration, and subjected to Western blotting. B) Time course (at 100 ng/ml). Total protein were isolated from PANC-1 cells for Western 
blotting after different duration of EGF. EGF stimulates HCCR-1 expression in PANC-1 cells in a dose- and time-dependent manner. Tubulin was used 
as a loading control. Blocking PI3K or mTOR signaling with either C) LY294002 (50 μg/mL) or D) rapamycin (10 ng/ml), respectively, suppresses the 
EGF (100 ng/mL)-mediated HCCR-1 expression in PANC-1 cells. E) EGF induces the activity of Akt within 2 min at highest level with gradual decrease.Xu et al. BMC Cancer 2010, 10:161
http://www.biomedcentral.com/1471-2407/10/161
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were obtained in other two pancreatic cancer cells,
SW1990 and CFPAC-1, but the EGF-induced HCCR-1
expression was much significant in PANC-1 cells (data
not shown). To further define the HCCR-1 signaling
pathway in pancreatic cancer cells, either PI3-kinase
inhibitor (LY294002) or mTOR inhibitor (rapamycin) was
pre-treated on PANC-1 cells and then they were re-stim-
ulated with EGF. Our result shows that both LY294002
and rapamycin inhibit the up-regulation effect of HCCR-
1 by EGF (Figs. 3C and 4D), suggesting that EGF-induced
HCCR-1 expression is mediated by PI3K/mTOR signaling
in pancreatic cancer. Akt is a key downstream signaling
component of the PI3K pathway [27,28], and mediates
the downstream effects of mTOR by inducing cell growth,
proliferation and survival of malignant cells [29,30]. In
cancer cells, Akt is constitutively activated by phosphory-
lation on residues of serine and threonine at sites 473 and
308, respectively [27]. We examined whether Akt
becomes phosphorylated on PANC-1 cells when they are
treated with EGF like in other cancer cells. Akt was acti-
vated by phosphorylation within 2 min after EGF treat-
ment (Fig. 3E), indicating that Akt serves as a
downstream effector of EGF signaling pathway on
PANC-1 cells. Taken together, our results suggest that
PI3K/mTOR signaling pathway involving Akt plays an
essential role for regulating the HCCR-1 levels.
Akt induces HCCR-1 overexpression by enhancing its 
promoter activity in PANC-1 cells
In order to gain a better insight into the Akt signaling
mechanism on regulating HCCR-1 levels, stable cells
lines of PANC-1 cells were established with CA-Akt con-
structs and DN-Akt mutants. As shown in Fig. 4A, the
over-expression of constitutively active form of Akt
increased the HCCR-1 levels on stable PANC-1 cell lines
whereas dominant negative mutant form of Akt failed to
induce HCCR-1 expression as confirmed by western blot-
ting. This result demonstrates that HCCR-1 expression is
driven by Akt activity. Previous works have shown that
Akt is a key modulator of the HCCR-1 promoter in K562
and NIH/3T3 cells. To test whether Akt regulates the
HCCR-1 promoter activity in PANC-1 cells, we generated
three reporter constructs containing different proximal
promoter regions of HCCR-1 (pGL3/HCCR-1-P1196,
pGL3/HCCR-1-P504, and pGL3/HCCR-1-P423). The
stable PANC-1 cell lines carrying either CA-Akt or DN-
Akt were transfected with reporter constructs and they
were assayed for luciferase activity (Fig. 4B). Consistent
with the previous work [21], the promoter activity of
pGL3/HCCR-1-P423 was the lowest in PANC-1 cells
compared to the other two (pGL3/HCCR-1-P1196,
pGL3/HCCR-1-P504). However, the promoter activity of
pGL3/HCCR-1-P1196 was slightly higher than that of
pGL3/HCCR-1-P504 in PANC-1 unlike in K562 and
NIH3T3. Interestingly, however, the promoter activity of
both pGL3/HCCR-1-P1196 and pGL3/HCCR-1-P504
constructs was enhanced by a constitutively active form
of Akt whereas it was down-regulated by a dominant neg-
ative mutant form of Akt. This result strongly supports
that Akt activity directly regulates the HCCR-1 promoter
function. In addition, the Akt-responding element seems
to be located in between +30 and -1166 region of HCCR-
1 gene. Therefore, Akt seems to be a key regulator of
HCCR-1 promoter in pancreatic cancer cells.
Discussion
Despite of recent advances in understanding the molecu-
lar pathogenesis on pancreatic cancer, this disease still
remains as one of the most aggressive human solid
tumors. The pancreatic cancer is characterized by the
rapid growth, metastatic spread, and resistance to che-
motherapeutic drugs. This challenging feature of the pan-
creatic cancer has become the major cause of 40,000
estimated deaths/year in Europe, and nearly 30,000
deaths/year in the USA [31,32].
The accumulated knowledge on the molecular basis of
the pancreatic cancers has revealed that many molecular
events are responsible for initiating pancreatic cancers
and its progression. First, gain or loss mutations in onco-
genes or tumor suppressors occur in most of pancreatic
cancers (for example, K-ras and p53 mutations found in
75-90% and 50% of pancreatic cancers, respectively) [33].
Secondly, a variety of growth factors and their receptors
are expressed at increased levels, such as transforming
growth factor-β (TGF-β), epidermal growth factor (EGF),
fibroblast growth factor (FGF), and insulin growth factor
(IGF), and their receptors. These molecules serve to stim-
ulate the pancreatic cancer cell growth in an autocrine
and/or paracrine manner [34,35]. Third, it is also known
that molecular aberrations in signaling pathways contrib-
ute to the pancreatic cancer. They include Ras-Raf-MEK
signaling pathway, the PI3K/Akt signaling pathway, and
the signal transducer and activator of transcription
(STAT) family of proteins. In addition to molecular
lesions described above, there are many other molecular
alterations associated with the pancreatic cancer such as
mutations affecting p16INKA/retinoblastoma proteins
and reactivation of Notch and Hedgehog signaling.
Based on these findings on the molecular alterations of
the pancreatic cancers, many therapeutic drugs have
been developed by targeting K-ras, EGFR and PI3K/Akt
signaling components. Although these therapeutics have
promoted the survival of patients, only pancreatic resec-
tion improves the survival significantly in patients with
advanced pancreatic cancers. Despite of numerous
efforts made in exploiting novel targets for pancreatic
cancers management, they have been elusive. This meansXu et al. BMC Cancer 2010, 10:161
http://www.biomedcentral.com/1471-2407/10/161
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that more extensive studies are needed to understand this
disease.
The HCCR-1 gene was first discovered from the cervi-
cal cancer in which its expression is elevated [15]. It is
over-expressed in many different cancers including leuke-
mia, lymphoma, and carcinomas of the breast, kidney,
ovary , stomach, and colon. This suggests that HCCR -1
might provide the fundamental function essential for
tumor growth and survival. Indeed, HCCR-1 was capable
of transforming, almost as efficient as Ras, the NIH/3T3
and Rat1 cells. It also could impart those cells the ability
to form the tumor in vivo. The underlying mechanism on
Figure 4 Akt induces HCCR-1 overexpression by increasing its promoter activity in PANC-1 cells. A) Stable transfectants with two types of con-
stitutively active Akt (CA-Akt1 or 2) induced HCCR-1 expression (lane3,4), whereas dominant negative Akt mutants (DN-Akt1 or 2) failed to induce its 
expression(lane1,2), compared with vector control(lane5,6). Akt is a doublet protein as shown in the figure. Tubulin, an equivalent loading control of 
proteins in western blot assays. B) Akt transactivates the promoter activity of HCCR-1. The transfectants applied in Fig. 4A were co-transfected with 
reporter plasmids containing three different constructs of HCCR-1 promoter (for details, see Materials and Methods) and internal control vector. The 
promoter activity of both pGL3/HCCR-1-P1196 and pGL3/HCCR-1-P504 constructs was enhanced by a constitutively active form of Akt whereas it was 
down-regulated by a dominant negative mutant form of Akt (P < 0.05, multiple factor ANOVA), and this was not found in the pGL3/HCCR-1-P423 con-
struct. The data are expressed as the mean ± SEM of three separate experiments.Xu et al. BMC Cancer 2010, 10:161
http://www.biomedcentral.com/1471-2407/10/161
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the HCCR-1-mediated tumorigenesis was p53 stabiliza-
tion concomitant with suppression of p21 and Bax, and
the interaction with its binding proteins [15]. The subse-
quent studies on HCCR-1 revealed that it also exerts an
oncogenic activity in the breast and colon cancers [16,20].
It was the PI3K/Akt pathway that governs the expression
of HCCR-1 in cancer cell lines such as K562, MCF7, and
A549 [21]. As explained above, PI3K/Akt pathway is one
of the downstream signaling pathways triggered by EGF-
EGFR ligation, and it regulates cell survival, proliferation,
and resistance to apoptosis.
Previous studies suggested that the COOH-terminal
sequence YLGTRR appears to be a major linear epitope
of HCCR [18]. In the present study, we successfully devel-
oped a highly efficient and specific polyclonal antibody
against HCCR by cloning the cDNA encoding a polypep-
tide homologus to the 167th - 360th amino acid residues
of HCCR into the pMBP vector. Using the polyclonal
antibody, we found that HCCR-1 is over-expressed in
most of pancreatic tumors and its expression level is asso-
ciated with the progression of the disease (Fig. 1C). On
the contrary, it is expressed less and at low levels in para-
neoplastic tissues and benign tumors (p < 0.01) (Table 1).
This is consistent with our idea that HCCR-1 function is
required for the pancreatic cancer progression.
Interestingly, the over-expression of HCCR-1 found in
most of pancreatic cancers was triggered by EGF signal-
ing which has been already known to regulate the pancre-
atic cancer development. Upon EGF stimulation, EGFR
initiates the activation of proliferative and survival signal-
ing pathways, such as the Ras/Raf/MEK (MAPK) and
Akt/mTOR cascades [36]. Our study clearly shows that
EGF-induced over-expression of HCCR-1 is mediated by
the PI3K/Akt/mTOR signaling pathway. It suggests that
HCCR-1 is one of the down-stream components of the
EGF-triggered PI3K/Akt/mTOR signaling which plays a
pivotal role in the pancreatic cancer tumorigenesis. Dur-
ing this process, activated Akt directly modulated the
promoter activity of HCCR-1 located in the 5'upstream
region of HCCR-1 gene. Since the -1166 to +30 region of
HCCR-1 gene contains many other putative binding
motifs for other transcription factors such as E2F, GATA-
1, and estrogen (estrogen-related) [21], further investiga-
tion is needed to identify other potential mediators regu-
lating the HCCR-1 expressions in the pancreatic cancers.
Conclusions
In conclusion, although further studies are required to
fully address the molecular mechanism of HCCR-1 on
the pancreatic tumorigenesis, our result provides the
insight on the role of HCCR-1 and its involvement in the
pancreatic cancer via the EGF-triggered PI3K/Akt/
mTOR pathway. Therefore, our work suggests that
HCCR-1 could be a potential target for pancreatic cancer
therapeutics.
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